Government-Owned Inventions; Availability for Licensing, 68455-68456 [2014-27083]

Download as PDF Federal Register / Vol. 79, No. 221 / Monday, November 17, 2014 / Notices Dated: November 10, 2014. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2014–27039 Filed 11–14–14; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration asabaliauskas on DSK5VPTVN1PROD with NOTICES Advisory Commission on Childhood Vaccines; Notice of Meeting In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), notice is hereby given of the following meeting: Name: Advisory Commission on Childhood Vaccines (ACCV) Date And Time: December 4, 2014, 10:00 a.m. to 4:00 p.m. EDT Place: Audio Conference Call and Adobe Connect Pro The ACCV will meet on Thursday, December 4, 2014, from 10:00 a.m. to 4:00 p.m. (EDT). The public can join the meeting by: 1. (Audio Portion) Calling the conference Phone Number 877–917– 4913 and providing the following information: Leader’s Name: Dr. A. Melissa Houston Password: ACCV 2. (Visual Portion) Connecting to the ACCV Adobe Connect Pro Meeting using the following URL: https:// hrsa.connectsolutions.com/accv/ (copy and paste the link into your browser if it does not work directly, and enter as a guest). Participants should call and connect 15 minutes prior to the meeting in order for logistics to be set up. If you have never attended an Adobe Connect meeting, please test your connection using the following URL: https:// hrsa.connectsolutions.com/common/ help/en/support/meeting_test.htm and get a quick overview by following URL: http://www.adobe.com/go/connectpro_ overview. Call (301) 443–6634 or send an email to aherzog@hrsa.gov if you are having trouble connecting to the meeting site. Agenda: The agenda items for the December 2014 meeting will include, but are not limited to: updates from the Division of Injury Compensation Programs (DICP), Department of Justice (DOJ), National Vaccine Program Office (NVPO), Immunization Safety Office (Centers for Disease Control and Prevention), National Institute of Allergy and Infectious Diseases (National Institutes of Health), and the Center for Biologics, Evaluation and Research (Food and Drug VerDate Sep<11>2014 17:14 Nov 14, 2014 Jkt 235001 Administration). A draft agenda and additional meeting materials will be posted on the ACCV Web site (http:// www.hrsa.gov/vaccinecompensation/ accv.htm) prior to the meeting. Agenda items are subject to change as priorities dictate. Public Comment: Persons interested in providing an oral presentation should submit a written request, along with a copy of their presentation to: Annie Herzog, DICP, Healthcare Systems Bureau (HSB), Health Resources and Services Administration (HRSA), Room 11C–26, 5600 Fishers Lane, Rockville, MD 20857 or email: aherzog@hrsa.gov. Requests should contain the name, address, telephone number, email address, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative. The allocation of time may be adjusted to accommodate the level of expressed interest. DVIC will notify each presenter by email, mail, or telephone of their assigned presentation time. Persons who do not file an advance request for a presentation, but desire to make an oral statement, may announce it at the time of the public comment period. Public participation and ability to comment will be limited to space and time as it permits. FOR FURTHER INFORMATION CONTACT: Anyone requiring information regarding the ACCV should contact Annie Herzog, DICP, HSB, HRSA, Room 11C–26, 5600 Fishers Lane, Rockville, Maryland 20857, telephone (301) 443–6593, or email: aherzog@hrsa.gov. Dated: November 7, 2014. Jackie Painter, Acting Director, Division of Policy and Information Coordination. [FR Doc. 2014–27188 Filed 11–14–14; 8:45 am] BILLING CODE 6705–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious commercialization SUMMARY: PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 68455 of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301– 496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology descriptions follow. Heterocyclic Compounds for the Treatment of Hepatitis C Virus Description of Technology: The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that have changed the HCV treatment paradigm. However, the effectiveness of these new drugs can vary depending on the HCV genotype. Furthermore, all oral, interferon free therapeutic regimens for HCV infection will need combinations of drugs that target different aspects of the HCV life cycle. Thus, there is still the need for additional new therapeutics against HCV. The subject technologies are aryloxazole based small molecules that are potent inhibitors of HCV infection and replication. The compounds exhibit synergy with currently available therapeutics for HCV and represent a new class of anti-HCV compounds. The compounds affect the entry step of HCV infection, a step not targeted by currently available therapeutics against HCV. Potential Commercial Applications: Prevention and treatment of HCV infection. Competitive Advantages: • Potent inhibitors of HCV infection and replication. • Show synergistic effect with currently available HCV therapeutics. • Represent new class of HCV inhibitors that target the entry step of HCV infection. Development Stage: • Early-stage. • In vitro data available. E:\FR\FM\17NON1.SGM 17NON1 68456 Federal Register / Vol. 79, No. 221 / Monday, November 17, 2014 / Notices asabaliauskas on DSK5VPTVN1PROD with NOTICES Inventors: Jake Tsanyang Liang (NIDDK), Zongyi Hu (NIDDK), Juan Jose Marugan (NCATS), Noel Terrance Southhall (NCATS), Xin Hu (NCATS), Jingbo Xiao (NCATS), Shanshan He (NIDDK), Marc Ferrer-Alegre (NCATS), Wei Zhang (NCATS) Intellectual Property: HHS Reference No. E–161–2014/0—U.S. Provisional Patent Application No. 62/011,462 filed 12 June2014 Licensing Contact: Kevin W. Chang, Ph.D.; 301–435–5018; changke@ mail.nih.gov Autodock Vina Software Process for Efficient Large-Scale Cognate Ligand Screening Description of Technology: The invention pertains to software processes, additions, and docking approaches to Autodock Vina that speeds the rate and efficiency of analyzing ligand interactions with a receptor by cognate ligands and rewards conformations in the scoring algorithm for residue interactions that are based on the biological data. The score is multiplied by a weighting factor to control the degree of ligand-residue interactions that are considered. This multiplier is then added to the docking score for confirmation. This new scoring mechanism is used to score each compound in each generation of the evolutionary genetic algorithm. This docking approach can be used to score and rank compounds in large-scale virtual screening applications. The software includes logic for converting SDF formatted to an Autodock Vina compatible format (containing approx. 25,000 compounds each) and submits the job to the portable batch system on the computing cluster to convert into PDBC files (a concatenated filed type). Modified Vina software stores the analyzed binding pocket in RAM that does not have to be recomputed upon every docking process. This increases the efficiency of the docking algorithm by several orders of magnitude. The software on the head node intelligently monitors memory usage, CPU usage and docking speed. Based on this information, the head node elastically controls the load on each node. Potential Commercial Applications: • Drug screening. • Ligand identification. Competitive Advantages: • Speed. • Batch processing. • Efficient CPU processing. Development Stage: In vitro data available. Inventors: Marvin Gershengorn, Umesh Padia, Janak Padia, Elizabeth Geras-Raaka (all of NIDDK). VerDate Sep<11>2014 17:14 Nov 14, 2014 Jkt 235001 Intellectual Property: HHS Reference No. E–289–2014/0—Software Tool. Patent protection is not being pursued for this technology. Licensing Contact: Michael Shmilovich, Esq.; 301–435–5019; shmilovm@mail.nih.gov. Collaborative Research Opportunity: The National Institutes of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Cognate Ligand Identification. For collaboration opportunities, please contact Anna Amar at 301–451–2305 or aamar@mail.nih.gov. Dated: November 10, 2014. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2014–27083 Filed 11–14–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health: Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel; NIMH Career Transition Award for TenureTrack and Tenured Intramural Investigators (K22). Date: December 2, 2014. Time: 12:30 p.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Ingrid Y. Li, Ph.D., Health Science Administrator Division of Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center, 6001 Executive Blvd., Room 6154–C, PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 Bethesda, MD 20892, 301–443–1421, ili1@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS) Dated: November 7, 2014. Carolyn A. Baum, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2014–27060 Filed 11–14–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Environmental Health Sciences; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel; Alternative Toxicological Methods Support Contract for the National Toxicology Program (NTP). Date: December 11, 2014. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute of Environmental Health Sciences, Keystone Building, Conference Room 2166, 530 Davis Drive, Research Triangle Park, NC 27709, (Telephone Conference Call). Contact Person: RoseAnne M. McGee, Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Sciences, P.O. Box 12233, MD EC–30, Research Triangle Park, NC 27709 (919) 541– 0752, mcgee1@niehs.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, E:\FR\FM\17NON1.SGM 17NON1

Agencies

[Federal Register Volume 79, Number 221 (Monday, November 17, 2014)]
[Notices]
[Pages 68455-68456]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-27083]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Heterocyclic Compounds for the Treatment of Hepatitis C Virus

    Description of Technology: The vast majority of people infected 
with Hepatitis C Virus (HCV) will have chronic infection. Over decades, 
this can lead to liver disease and liver cancer. In fact, HCV infection 
is the leading cause of liver transplants in the U.S. Several new drugs 
have recently come into the market that have changed the HCV treatment 
paradigm. However, the effectiveness of these new drugs can vary 
depending on the HCV genotype. Furthermore, all oral, interferon free 
therapeutic regimens for HCV infection will need combinations of drugs 
that target different aspects of the HCV life cycle. Thus, there is 
still the need for additional new therapeutics against HCV.
    The subject technologies are aryloxazole based small molecules that 
are potent inhibitors of HCV infection and replication. The compounds 
exhibit synergy with currently available therapeutics for HCV and 
represent a new class of anti-HCV compounds. The compounds affect the 
entry step of HCV infection, a step not targeted by currently available 
therapeutics against HCV.
    Potential Commercial Applications: Prevention and treatment of HCV 
infection.
    Competitive Advantages:
     Potent inhibitors of HCV infection and replication.
     Show synergistic effect with currently available HCV 
therapeutics.
     Represent new class of HCV inhibitors that target the 
entry step of HCV infection.
    Development Stage:
     Early-stage.
     In vitro data available.

[[Page 68456]]

    Inventors: Jake Tsanyang Liang (NIDDK), Zongyi Hu (NIDDK), Juan 
Jose Marugan (NCATS), Noel Terrance Southhall (NCATS), Xin Hu (NCATS), 
Jingbo Xiao (NCATS), Shanshan He (NIDDK), Marc Ferrer-Alegre (NCATS), 
Wei Zhang (NCATS)
    Intellectual Property: HHS Reference No. E-161-2014/0--U.S. 
Provisional Patent Application No. 62/011,462 filed 12 June2014
    Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018; 
changke@mail.nih.gov

Autodock Vina Software Process for Efficient Large-Scale Cognate Ligand 
Screening

    Description of Technology: The invention pertains to software 
processes, additions, and docking approaches to Autodock Vina that 
speeds the rate and efficiency of analyzing ligand interactions with a 
receptor by cognate ligands and rewards conformations in the scoring 
algorithm for residue interactions that are based on the biological 
data. The score is multiplied by a weighting factor to control the 
degree of ligand-residue interactions that are considered. This 
multiplier is then added to the docking score for confirmation. This 
new scoring mechanism is used to score each compound in each generation 
of the evolutionary genetic algorithm. This docking approach can be 
used to score and rank compounds in large-scale virtual screening 
applications. The software includes logic for converting SDF formatted 
to an Autodock Vina compatible format (containing approx. 25,000 
compounds each) and submits the job to the portable batch system on the 
computing cluster to convert into PDBC files (a concatenated filed 
type). Modified Vina software stores the analyzed binding pocket in RAM 
that does not have to be recomputed upon every docking process. This 
increases the efficiency of the docking algorithm by several orders of 
magnitude. The software on the head node intelligently monitors memory 
usage, CPU usage and docking speed. Based on this information, the head 
node elastically controls the load on each node.
    Potential Commercial Applications:
     Drug screening.
     Ligand identification.
    Competitive Advantages:
     Speed.
     Batch processing.
     Efficient CPU processing.
    Development Stage: In vitro data available.
    Inventors: Marvin Gershengorn, Umesh Padia, Janak Padia, Elizabeth 
Geras-Raaka (all of NIDDK).
    Intellectual Property: HHS Reference No. E-289-2014/0--Software 
Tool. Patent protection is not being pursued for this technology.
    Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019; 
shmilovm@mail.nih.gov.
    Collaborative Research Opportunity: The National Institutes of 
Diabetes and Digestive and Kidney Diseases is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize Cognate Ligand 
Identification. For collaboration opportunities, please contact Anna 
Amar at 301-451-2305 or aamar@mail.nih.gov.

    Dated: November 10, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-27083 Filed 11-14-14; 8:45 am]
BILLING CODE 4140-01-P